JP2013040176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013040176A5 JP2013040176A5 JP2012201762A JP2012201762A JP2013040176A5 JP 2013040176 A5 JP2013040176 A5 JP 2013040176A5 JP 2012201762 A JP2012201762 A JP 2012201762A JP 2012201762 A JP2012201762 A JP 2012201762A JP 2013040176 A5 JP2013040176 A5 JP 2013040176A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nitric oxide
- oxide precursor
- surgery
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 16
- 230000002980 postoperative effect Effects 0.000 claims 7
- 239000002243 precursor Substances 0.000 claims 7
- 230000002685 pulmonary effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 230000017531 blood circulation Effects 0.000 claims 4
- 238000007675 cardiac surgery Methods 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 230000007774 longterm Effects 0.000 claims 3
- 230000004143 urea cycle Effects 0.000 claims 3
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 206010051606 Necrotising colitis Diseases 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000007613 environmental effect Effects 0.000 claims 2
- 239000000543 intermediate Substances 0.000 claims 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 2
- 230000006442 vascular tone Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 206010063836 Atrioventricular septal defect Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000002457 bidirectional effect Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 201000003130 ventricular septal defect Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/785,374 | 2004-02-24 | ||
| US10/785,374 US9486429B2 (en) | 1999-06-01 | 2004-02-24 | Therapeutic methods employing nitric oxide precursors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554329A Division JP2007524695A (ja) | 2004-02-24 | 2005-02-24 | 一酸化窒素前駆体を用いる治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014165456A Division JP2015007090A (ja) | 2004-02-24 | 2014-08-15 | 一酸化窒素前駆体を用いる治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013040176A JP2013040176A (ja) | 2013-02-28 |
| JP2013040176A5 true JP2013040176A5 (enExample) | 2013-10-31 |
Family
ID=34911448
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554329A Pending JP2007524695A (ja) | 2004-02-24 | 2005-02-24 | 一酸化窒素前駆体を用いる治療方法 |
| JP2012201762A Pending JP2013040176A (ja) | 2004-02-24 | 2012-09-13 | 一酸化窒素前駆体を用いる治療方法 |
| JP2014165456A Pending JP2015007090A (ja) | 2004-02-24 | 2014-08-15 | 一酸化窒素前駆体を用いる治療方法 |
| JP2015232749A Expired - Lifetime JP6239571B2 (ja) | 2004-02-24 | 2015-11-30 | 一酸化窒素前駆体を用いる医薬組成物 |
| JP2017152929A Expired - Lifetime JP6395912B2 (ja) | 2004-02-24 | 2017-08-08 | 一酸化窒素前駆体を用いる医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554329A Pending JP2007524695A (ja) | 2004-02-24 | 2005-02-24 | 一酸化窒素前駆体を用いる治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014165456A Pending JP2015007090A (ja) | 2004-02-24 | 2014-08-15 | 一酸化窒素前駆体を用いる治療方法 |
| JP2015232749A Expired - Lifetime JP6239571B2 (ja) | 2004-02-24 | 2015-11-30 | 一酸化窒素前駆体を用いる医薬組成物 |
| JP2017152929A Expired - Lifetime JP6395912B2 (ja) | 2004-02-24 | 2017-08-08 | 一酸化窒素前駆体を用いる医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9486429B2 (enExample) |
| EP (3) | EP2319507A1 (enExample) |
| JP (5) | JP2007524695A (enExample) |
| CN (1) | CN1946388B (enExample) |
| AU (2) | AU2005216270A1 (enExample) |
| BR (1) | BRPI0507960A (enExample) |
| IL (4) | IL177224A (enExample) |
| WO (1) | WO2005082042A2 (enExample) |
| ZA (2) | ZA200606575B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| CA2642761A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
| DE102006021406B4 (de) * | 2006-05-08 | 2008-08-07 | B.R.A.H.M.S Aktiengesellschaft | In vitro Verfahren zur Früherkennung von arznei- und suchtmittelinduzierten Leberschäden und zur Erkennung der bereits erreichten Stufe der Leberschädigung |
| FR2907011B1 (fr) * | 2006-10-17 | 2010-05-14 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des etats de denutrition |
| US7844609B2 (en) | 2007-03-16 | 2010-11-30 | Expanse Networks, Inc. | Attribute combination discovery |
| FR2913885B1 (fr) * | 2007-03-22 | 2012-07-20 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines |
| WO2009099998A2 (en) * | 2008-01-31 | 2009-08-13 | Vanderbilt University | Therapeutic treatment for lung conditions |
| PL2240170T3 (pl) * | 2008-01-31 | 2019-11-29 | Univ Vanderbilt | Sposoby i kompozycje do leczenia wieńcowego i tętniczego tętniakowego krwotoku podpajęczynówkowego |
| AU2014204490B2 (en) * | 2008-01-31 | 2016-05-12 | Vanderbilt University | Therapeutic treatment for lung condtions |
| AU2009293475A1 (en) | 2008-09-19 | 2010-03-25 | Nestec S.A. | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| US8108406B2 (en) | 2008-12-30 | 2012-01-31 | Expanse Networks, Inc. | Pangenetic web user behavior prediction system |
| EP2370929A4 (en) | 2008-12-31 | 2016-11-23 | 23Andme Inc | SEARCH FOR RELATED IN A DATABASE |
| WO2011051742A1 (en) * | 2009-10-28 | 2011-05-05 | Modutech S.A. | Preparation comprising amino acids and plants and its activity in the alcohol detoxification |
| US9572848B1 (en) | 2014-03-26 | 2017-02-21 | Aemes Research L.L.L.P. | Composition of matter for sexual dysfunction |
| BR112017025768A2 (pt) | 2015-06-29 | 2018-08-14 | Univ Vanderbilt | administração intravenosa de citrulina durante cirurgia |
| US10265286B2 (en) | 2016-12-28 | 2019-04-23 | Vanderbilt University | Sequelae of cardiopulmonary bypass-induced pulmonary injury |
| JP2018114414A (ja) * | 2018-05-07 | 2018-07-26 | 株式会社大一商会 | 遊技機 |
| WO2020176722A1 (en) * | 2019-02-27 | 2020-09-03 | The Regents Of The University Of Michigan | Carbamoyl phosphate synthatase-1 for the treatment and prevention of internal tissue injury |
| JP2022535927A (ja) | 2019-06-05 | 2022-08-10 | アスクレピオン ファーマシューティカルズ， エルエルシー | シトルリンの合成および精製の改善された方法 |
| US12064409B2 (en) | 2021-06-22 | 2024-08-20 | Vanderbilt University | Action of L-citrulline to prevent or treat endothelial dysfunction |
| US20230404956A1 (en) * | 2022-06-21 | 2023-12-21 | Asklepion Pharmaceuticals Llc | Therapeutic window for citrulline therapy |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1005A (en) * | 1838-11-12 | Ing and heating booms and other apabtments beqtjibing abtrficial | ||
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| NL8102724A (nl) | 1980-07-11 | 1982-02-01 | Stamicarbon | Werkwijze voor de bereiding van copolymeren van etheen met tenminste een ander 1-alkeen. |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5573933A (en) | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
| US4996236A (en) | 1988-06-22 | 1991-02-26 | Takeda Chemical Industries, Ltd. | Therapeutic composition for hepatic encephalopathy |
| US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
| US5489742A (en) | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
| US5641484A (en) | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5643567A (en) | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| WO1992010573A1 (en) | 1990-12-04 | 1992-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the suppression of neu mediated transformation |
| DE122007000103I1 (de) | 1990-12-05 | 2008-04-03 | Gen Hospital Corp | Verwendung von NO zur Behandlung der persistenten pulmonalen Hypertonie des Neugeborenen |
| US5550316A (en) | 1991-01-02 | 1996-08-27 | Fox Chase Cancer Center | Transgenic animal model system for human cutaneous melanoma |
| US5550024A (en) | 1991-04-19 | 1996-08-27 | Biotechnology Research & Development Corporation | Genetic markers for pig litter size |
| US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
| US5286739A (en) | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
| US5374651A (en) | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
| US5385940A (en) | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| WO1994016740A1 (en) | 1993-01-29 | 1994-08-04 | Brigham And Women's Hospital | The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury |
| US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5646008A (en) | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
| US5625125A (en) | 1994-08-09 | 1997-04-29 | Dnx Biotherapeutics | Phospholipase A2 expressing transgenic animals |
| US5543430A (en) | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
| US5648061A (en) | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
| US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US5874471A (en) | 1997-02-27 | 1999-02-23 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
| US6028107A (en) | 1997-02-27 | 2000-02-22 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
| AU9596698A (en) | 1997-10-15 | 1999-05-03 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| US6796966B2 (en) | 1997-10-15 | 2004-09-28 | Jeffrey E. Thomas | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal |
| US20010056068A1 (en) | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
| US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| US6182295B1 (en) | 1999-06-14 | 2001-02-06 | Kevin Sciglia | Hat |
| JP3672871B2 (ja) * | 1999-11-15 | 2005-07-20 | エルジー エレクトロニクス インコーポレーテッド | サイクロン集塵装置の集塵筒結合装置 |
| JP3506114B2 (ja) | 2000-01-25 | 2004-03-15 | 株式会社ニコン | モニタ装置及びこのモニタ装置を具えた研磨装置及び研磨方法 |
| US6689810B2 (en) | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| AU2002332929A1 (en) | 2001-09-07 | 2003-03-24 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39 |
| US20030134332A1 (en) * | 2001-11-28 | 2003-07-17 | Boykin Joseph V. | Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
| ES2380046T3 (es) | 2005-01-06 | 2012-05-08 | Discovery Laboratories, Inc. | Régimen para el tratamiento con tensioactivos para tratar o prevenir la displasia broncopulmonar |
| WO2007065147A2 (en) | 2005-12-01 | 2007-06-07 | Nps Pharmaceuticals, Inc. | A biomarker of improved intestinal function |
| PL2240170T3 (pl) | 2008-01-31 | 2019-11-29 | Univ Vanderbilt | Sposoby i kompozycje do leczenia wieńcowego i tętniczego tętniakowego krwotoku podpajęczynówkowego |
| WO2009099998A2 (en) | 2008-01-31 | 2009-08-13 | Vanderbilt University | Therapeutic treatment for lung conditions |
-
2004
- 2004-02-24 US US10/785,374 patent/US9486429B2/en not_active Expired - Fee Related
-
2005
- 2005-02-24 WO PCT/US2005/006081 patent/WO2005082042A2/en not_active Ceased
- 2005-02-24 JP JP2006554329A patent/JP2007524695A/ja active Pending
- 2005-02-24 EP EP10184493A patent/EP2319507A1/en not_active Ceased
- 2005-02-24 EP EP18158829.4A patent/EP3351241A1/en not_active Ceased
- 2005-02-24 AU AU2005216270A patent/AU2005216270A1/en not_active Abandoned
- 2005-02-24 BR BRPI0507960-8A patent/BRPI0507960A/pt not_active Application Discontinuation
- 2005-02-24 EP EP05723789A patent/EP1718289A4/en not_active Withdrawn
- 2005-02-24 CN CN2005800126935A patent/CN1946388B/zh not_active Expired - Lifetime
-
2006
- 2006-08-02 IL IL177224A patent/IL177224A/en active IP Right Grant
- 2006-08-07 ZA ZA2006/06575A patent/ZA200606575B/en unknown
-
2008
- 2008-07-18 ZA ZA2008/06276A patent/ZA200806276B/en unknown
-
2009
- 2009-07-31 AU AU2009203177A patent/AU2009203177B2/en not_active Expired
-
2012
- 2012-09-13 JP JP2012201762A patent/JP2013040176A/ja active Pending
-
2013
- 2013-04-23 IL IL225912A patent/IL225912A/en active IP Right Grant
- 2013-06-13 IL IL225911A patent/IL225911A/en active IP Right Grant
-
2014
- 2014-04-27 IL IL232265A patent/IL232265A0/en unknown
- 2014-08-15 JP JP2014165456A patent/JP2015007090A/ja active Pending
-
2015
- 2015-11-30 JP JP2015232749A patent/JP6239571B2/ja not_active Expired - Lifetime
-
2016
- 2016-11-04 US US15/343,998 patent/US20170119715A1/en not_active Abandoned
-
2017
- 2017-08-08 JP JP2017152929A patent/JP6395912B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013040176A5 (enExample) | ||
| JP2015007090A5 (enExample) | ||
| JP2011251155A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2010270124A5 (enExample) | ||
| JP2012529523A5 (enExample) | ||
| JP2011511006A5 (ja) | 肺病態に対する医薬組成物 | |
| JP2015534562A5 (enExample) | ||
| JP2016516020A5 (enExample) | ||
| EA201290575A1 (ru) | Ингибиторы вирусов flaviviridae | |
| JP2010059183A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| RU2013149168A (ru) | Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования | |
| JP2011225596A5 (enExample) | ||
| RU2010132581A (ru) | Способы терапии заболеваний легких | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2014505107A5 (enExample) | ||
| JP2012517478A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2017530163A5 (enExample) | ||
| JP2018503685A5 (enExample) | ||
| JP2015516419A5 (enExample) |